CA3033846C - CHIMERIC ANTIGEN RECEPTOR WITH DOMAIN I SPECIFIC TO INTERCELLULAR ADHESION MOLECULE 1 - Google Patents

CHIMERIC ANTIGEN RECEPTOR WITH DOMAIN I SPECIFIC TO INTERCELLULAR ADHESION MOLECULE 1

Info

Publication number
CA3033846C
CA3033846C CA3033846A CA3033846A CA3033846C CA 3033846 C CA3033846 C CA 3033846C CA 3033846 A CA3033846 A CA 3033846A CA 3033846 A CA3033846 A CA 3033846A CA 3033846 C CA3033846 C CA 3033846C
Authority
CA
Canada
Prior art keywords
cells
car
icam
domain
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3033846A
Other languages
English (en)
French (fr)
Other versions
CA3033846A1 (en
Inventor
Moonsoo Jin
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of CA3033846A1 publication Critical patent/CA3033846A1/en
Application granted granted Critical
Publication of CA3033846C publication Critical patent/CA3033846C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
CA3033846A 2016-09-02 2017-08-11 CHIMERIC ANTIGEN RECEPTOR WITH DOMAIN I SPECIFIC TO INTERCELLULAR ADHESION MOLECULE 1 Active CA3033846C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662383139P 2016-09-02 2016-09-02
US62/383,139 2016-09-02
US201662419817P 2016-11-09 2016-11-09
US62/419,817 2016-11-09
PCT/US2017/046630 WO2018052594A1 (en) 2016-09-02 2017-08-11 I domain chimeric antigen receptor specific to icam-1

Publications (2)

Publication Number Publication Date
CA3033846A1 CA3033846A1 (en) 2018-03-22
CA3033846C true CA3033846C (en) 2025-03-11

Family

ID=61281980

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3033846A Active CA3033846C (en) 2016-09-02 2017-08-11 CHIMERIC ANTIGEN RECEPTOR WITH DOMAIN I SPECIFIC TO INTERCELLULAR ADHESION MOLECULE 1

Country Status (10)

Country Link
US (6) US10428136B2 (cg-RX-API-DMAC7.html)
EP (1) EP3522718B1 (cg-RX-API-DMAC7.html)
JP (1) JP6996772B2 (cg-RX-API-DMAC7.html)
KR (1) KR102613109B1 (cg-RX-API-DMAC7.html)
CN (1) CN108697096B (cg-RX-API-DMAC7.html)
AU (1) AU2017325678B2 (cg-RX-API-DMAC7.html)
CA (1) CA3033846C (cg-RX-API-DMAC7.html)
ES (1) ES2971550T3 (cg-RX-API-DMAC7.html)
SG (1) SG11201901505SA (cg-RX-API-DMAC7.html)
WO (2) WO2018052594A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201901505SA (en) 2016-09-02 2019-03-28 Univ Cornell I domain chimeric antigen receptor specific to icam-1
JP2020505034A (ja) 2017-01-20 2020-02-20 ジュノ セラピューティクス ゲーエムベーハー 細胞表面コンジュゲートならびに関連する細胞組成物および方法
AU2018250336B2 (en) * 2017-04-07 2025-02-20 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
US11866494B2 (en) * 2018-08-31 2024-01-09 Innovative Cellular Therapeutics Holdings, Ltd. CAR T therapy through uses of co-stimulation
CN116600819A (zh) * 2020-12-09 2023-08-15 艾弗依姆恩治疗公司 靶向epcam和icam-1的双嵌合抗原受体
CN118146395A (zh) * 2021-02-08 2024-06-07 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
WO2024055075A1 (en) * 2022-09-14 2024-03-21 Biosceptre (Aust) Pty Ltd In vivo detection of immune cells
US12385818B2 (en) 2023-02-14 2025-08-12 Saudi Arabian Oil Company Modeling gas desorption in a subsurface reservoir
WO2024206155A1 (en) 2023-03-24 2024-10-03 Cornell University Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer
WO2025188678A1 (en) * 2024-03-04 2025-09-12 AffyImmune Therapeutics Inc. Icam-1 targeted car constructs and methods of treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2204183A1 (en) 1994-11-01 1996-05-09 Andrew Lawrence Feldhaus Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1171596A1 (en) 1999-04-16 2002-01-16 Celltech Therapeutics Limited Synthetic transmembrane components
CA2411962A1 (en) 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion
US7176187B2 (en) 2001-02-15 2007-02-13 Board Of Regents, The University Of Texas System Fusion proteins based upon somatostatin receptors
WO2007070488A2 (en) * 2005-12-12 2007-06-21 The Cbr Institute For Biomedical Research, Inc. Integrin alpha l i domain mutants with increased binding affinity
WO2012033901A2 (en) 2010-09-08 2012-03-15 The Board Of Regents Of The University Of Texas System Somatostatin receptor-based cancer therapy
KR101956751B1 (ko) * 2011-10-07 2019-03-11 고쿠리츠다이가쿠호진 미에다이가쿠 키메라 항원 수용체
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
EP3287135A4 (en) * 2015-03-20 2019-03-27 Mie University THERAPEUTICS RELATED TO THE SUPPRESSION OF PROLIFERATION AND METASTASIC FORMATION OF CANCER WITH CYTOTOXIC T CELLS RELEASED EXOSOMES AND FACED AGAINST ELECTRICITY / MESENCHYMAL CANCER CELLS
SG11201901505SA (en) * 2016-09-02 2019-03-28 Univ Cornell I domain chimeric antigen receptor specific to icam-1

Also Published As

Publication number Publication date
US10577408B2 (en) 2020-03-03
AU2017325678B2 (en) 2022-03-17
KR20190057072A (ko) 2019-05-27
CN108697096B (zh) 2022-05-03
US11634471B2 (en) 2023-04-25
US11046748B2 (en) 2021-06-29
SG11201901505SA (en) 2019-03-28
US10428136B2 (en) 2019-10-01
AU2017325678A1 (en) 2019-03-14
KR102613109B1 (ko) 2023-12-13
US12410235B2 (en) 2025-09-09
WO2018044534A1 (en) 2018-03-08
WO2018052594A1 (en) 2018-03-22
US20200181238A1 (en) 2020-06-11
JP6996772B2 (ja) 2022-02-21
ES2971550T3 (es) 2024-06-05
CA3033846A1 (en) 2018-03-22
US20200017573A1 (en) 2020-01-16
CN108697096A (zh) 2018-10-23
US20230265165A1 (en) 2023-08-24
JP2019530441A (ja) 2019-10-24
US20180066037A1 (en) 2018-03-08
US20180066035A1 (en) 2018-03-08
EP3522718A1 (en) 2019-08-14
EP3522718A4 (en) 2020-02-19
US20210309721A1 (en) 2021-10-07
US12325736B2 (en) 2025-06-10
EP3522718B1 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
US12410235B2 (en) I domain chimeric antigen receptor specific to ICAM-1
KR102809774B1 (ko) 합성 면역 수용체 및 이의 사용 방법
JP2021525509A (ja) 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
AU2021237570A1 (en) Novel antigen binding domains and synthetic antigen receptors incorporating the same
CN116348485A (zh) 提供用于过继性细胞疗法的靶向共刺激的受体
CN112533943B (zh) Il-13/il-4超级因子：免疫细胞靶向性构建体及其使用方法
WO2023230534A2 (en) Use of fusion constructs for il-2 independent t cell therapy
EP4466282A2 (en) Receptors providing targeted costimulation for adoptive cell therapy
AU2018308982A1 (en) Methods and compositions for the treatment of cancer
US12209137B2 (en) Antigen binding proteins specifically binding CT45
WO2025252993A1 (en) Chimeric antigen receptor targeting glioma-associated antigens
WO2024243429A2 (en) Use of fusion constructs for cd4+ t cell therapy
CN119894923A (zh) 包含tmigd2共刺激结构域的嵌合抗原受体及其相关使用方法
TW202216751A (zh) 用於過繼細胞療法之提供靶向共刺激之受體

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802